LAS 101057 is a potent, selective, and orally efficacious A2B receptor antagonist, was identified as a clinical development candidate. It inhibits agonist-induced IL-6 production in human fibroblasts and is active in an ovalbumin (OVA)-sensitized mouse model after oral administration, reducing airway hyperresponsiveness to methacholine, Th2 cytokine production and OVA-specific IgE levels.
